David A. Siegel Mei Pharma, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.22 - $8.4 $4,906 - $187,353	-22,304 Reduced 63.18%	13,000 $3,000
Q3 2022 Nov 14, 2022	SELL	$0.41 - $8.8 $1,394 - $29,920	-3,400 Reduced 8.78%	35,304 $14,000
Q2 2022 Aug 15, 2022	SELL	$0.42 - $0.65 $67,410 - $104,325	-160,500 Reduced 80.57%	38,704 $23,000
Q1 2022 May 16, 2022	BUY	$0.54 - $2.74 $14,202 - $72,062	26,300 Added 15.21%	199,204 $120,000
Q4 2021 Feb 14, 2022	SELL	$2.33 - $3.37 $289,386 - $418,554	-124,200 Reduced 41.8%	172,904 $462,000
Q3 2021 Nov 15, 2021	SELL	$2.52 - $2.99 $416,808 - $494,546	-165,400 Reduced 35.76%	297,104 $820,000
Q2 2021 Aug 16, 2021	SELL	$2.6 - $3.65 $954,460 - $1.34 Million	-367,100 Reduced 44.25%	462,504 $1.32 Million
Q1 2021 May 17, 2021	BUY	$2.73 - $4.5 $623,532 - $1.03 Million	228,400 Added 37.99%	829,604 $2.85 Million
Q4 2020 Feb 16, 2021	BUY	$2.6 - $3.32 $746,720 - $953,504	287,200 Added 91.46%	601,204 $1.59 Million
Q3 2020 Nov 16, 2020	BUY	$2.46 - $4.27 $226,320 - $392,839	92,000 Added 41.44%	314,004 $980,000
Q2 2020 Aug 14, 2020	BUY	$1.45 - $4.3 $92,220 - $273,480	63,600 Added 40.15%	222,004 $917,000
Q1 2020 May 15, 2020	BUY	$0.75 - $2.55 $59,250 - $201,450	79,000 Added 99.49%	158,404 $255,000
Q4 2019 Feb 14, 2020	BUY	$1.65 - $2.48 $71,280 - $107,136	43,200 Added 119.32%	79,404 $197,000
Q3 2019 Nov 14, 2019	BUY	$1.48 - $2.52 $5,920 - $10,080	4,000 Added 12.42%	36,204 $61,000
Q2 2019 Aug 14, 2019	BUY	$2.45 - $3.32 $31,360 - $42,496	12,800 Added 65.97%	32,204 $81,000
Q1 2019 May 15, 2019	BUY	$2.52 - $3.24 $5,292 - $6,804	2,100 Added 12.14%	19,404 $60,000
Q4 2018 Feb 14, 2019	BUY	$1.92 - $4.1 $33,223 - $70,946	17,304 New	17,304 $46,000

Others Institutions Holding MEIP

# of Institutions

Shares Held

Call Options Held

Put Options Held

Urban Wealth Management, LLC

2K
Shares

$5,777
0.0% of portfolio

View Full List

About MEI Pharma, Inc.

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $385M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

More about MEIP

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account